What’s next for boards in the UK pharma and life sciences industry? Navigating the challenges of innovation, productivity and ESG in a post Covid world.   The life science industry is in a dynamic phase of transformation which has been rapidly accelerated by the pandemic, with more workforce agility, shortening development and review times, increased speed to market, and greater efficiencies. In response to the pandemic, life sciences companies mobilized impressively to meet the needs of their employees, patients, customers, and communities. This mobilization, however, has upended well-established business norms, including about how and where people work.   panel guests discuss. -            Key priorities for boards in life sciences industry as they transition to the future of healthcare -            Harnessing opportunities from rapid digitalisation and tech disruption -            Building resilience in an era of rapid transformation -            Ideal skill sets and composition of life science company boards -            How boards in pharma and life science are integrating ESG and building trust with stakeholders